Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects ...

If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...

TransCon CNP matches BioMarin's Voxzogo for achondroplasia with plans for regulatory filings in 2025, showing potential for ...

In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies, ...

The company behind popular weight-loss drugs failed to disclose millions of pounds it paid to healthcare groups and patient ...

In a tearful video posted to Instagram, the 30-year-old from Pheonix, Arizona admitted she took the drug after struggling ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.